Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane

Iain RJ Macpherson1,3
Colin Lindsay2
Peter Canney3
1Centre for Oncology and Applied Pharmacology, University of Glasgow, Glasgow, Scotland, UK; 2Beatson Institute for Cancer Research, Glasgow, Scotland, UK; 3Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK

Abstract: Adjuvant hormonal therapy significantly reduces the risk of recurrence and death following surgery for estrogen receptor (ER)-positive early breast cancer. Previously, the gold standard hormonal therapy was tamoxifen, a selective modulator of the ER. However, large clinical trials conducted over the past decade have defined the efficacy of an alternative class of hormonal agent, namely the third-generation aromatase inhibitors (AIs): exemestane, letrozole, and anastrozole. On the basis of the pivotal International Exemestane Study (IES), exemestane, a steroidal third-generation AI, was licensed for the adjuvant treatment of postmenopausal women with ER-positive early breast cancer following 2–3 years of tamoxifen to complete a total of 5 years of adjuvant hormonal therapy. Here, we consider recent data to emerge primarily from the IES and Tamoxifen Exemestane Exemestane Adjuvant Multicenter trials and consider their implications for the role of exemestane in the adjuvant treatment of breast cancer.

Keywords: breast cancer, exemestane, aromatase, tamoxifen

Introduction

Breast cancer remains a major global health problem with 1.1 million new cases and 400,000 deaths occurring each year.1 The majority of breast cancers express the estrogen receptor (ER), are dependent on estrogen for growth and survival, and thus are potentially sensitive to manipulations that interfere with this pathway. Indeed, estrogen deprivation as a treatment for advanced breast cancer dates back to 1896 with George Beatson’s demonstration of tumor regression in premenopausal women treated with bilateral oophorectomy.2 However, a true mechanistic understanding of this phenomenon would not be possible until the discovery of estrogen in the following century. Attempts to medically block estrogen biosynthesis culminated in the development of aminoglutethamide, a first-generation aromatase inhibitor (AI), in the 1970s.3 At the same time, tamoxifen, a selective modulator of the ER, was under development.4 In subsequent head-to-head trials in patients with advanced breast cancer, tamoxifen demonstrated similar efficacy but improved tolerability in comparison to aminogluthethamide.1 The ensuing development of tamoxifen in the adjuvant setting has been one of the key developments in the treatment of breast cancer. Indeed, it is now apparent from the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) meta-analysis that around 5 years of adjuvant tamoxifen is associated with a 41% reduction in the annual recurrence rate and a 34% reduction in breast cancer-specific mortality.5

Aromatase, a member of the cytochrome P-450 family, catalyzes the final step in estrogen biosynthesis: the conversion of the androgens, androstenedione, and...
testosterone to the estrogens, estrone, and estradiol, respectively. In premenopausal women, the ovaries are the major site of estrogen biosynthesis and aromatase is expressed in the granulosa cells of the ovarian follicle. Ovarian aromatase is regulated within a powerful hypothalamic–pituitary feedback loop, and AIs are not able to robustly downregulate estrogen biosynthesis in the premenopausal woman. However, a distinct situation exists in postmenopausal women in whom ovarian production of estrogen ceases. Most circulating estrogen then derives from the conversion of circulating ovarian and adrenal androgens by aromatase expressed in adipose tissue and muscle. In addition, aromatase is expressed by both malignant and stromal cells in many breast tumors, resulting in local concentrations of estrogen far exceeding the circulating levels.  

Aminoglutethimide had a relatively low specificity with resulting off-target effects (blockade of 11β-hydroxylase necessitating cortisol replacement) and limited potency. However, the current third-generation AIs are highly potent and specific, with in vivo assays indicating 97.3%–99.1% inhibition of whole-body aromatase activity. The third-generation AIs fall into two distinct classes:

1. Steroidal inhibitors: Exemestane
   - Exemestane is an analog of the steroid androstenedione. It interacts with the steroid-binding region of the aromatase enzyme and forms an unbreakable covalent bond resulting in irreversible inhibition.

2. Nonsteroidal inhibitors: Anastrozole/Letrozole
   - These drugs competitively inhibit the hydroxylation reaction catalyzed by aromatase by binding with the heme iron of cytochrome P-450.
   - Several studies have confirmed a greater efficacy for third-generation AIs in comparison to tamoxifen in the advanced disease setting, thus prompting their investigation at earlier stages of disease.

**Exemestane**

Phase I studies of exemestane in healthy volunteers and breast cancer patients have demonstrated dose-dependent inhibition of plasma estrogen levels up to the 25 mg/d dose level, with no further inhibition achieved with doses up to 800 mg. Orally administered exemestane is rapidly absorbed, taking 2 hours for maximal concentrations to be reached. Exemestane is metabolized by the cytochrome P450 3A4 (CYP3A4) isoenzyme and by aldoketoreductases, followed by conjugation and excretion in urine and feces. The terminal half-life is around 27 hours. Inhibition of CYP3A4 was not associated with increased exposure to exemestane although drugs that induce CYP3A4 may reduce exposure to exemestane and efficacy. Following a single dose of exemestane, maximal suppression of estrogen was observed at 3 days and persisted for at least 5 days, consistent with a mechanism of irreversible enzyme inhibition. With daily dosing, steady-state levels are achieved in 7 days.

Investigation of exemestane in patients with advanced breast cancer demonstrated superiority to megestrol acetate and tamoxifen and confirmed activity against cancers resistant to tamoxifen or third-generation nonsteroidal AIs.

**Adjuvant trials of exemestane**

Given the superior efficacy of exemestane and other third-generation AIs in women with advanced breast cancer, it was a priority to delineate their efficacy in the adjuvant setting. In this regard, a variety of strategies by which AIs could either replace or be combined with tamoxifen have been investigated. These include up-front, sequential, switch, and extended strategies (Figure 1). In the case of exemestane, the most informative trials have been the International Exemestane Study (IES) and the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) study.

**International exemestane study**

This study randomized 4,724 postmenopausal women who were disease free after 2–3 years of adjuvant tamoxifen to receive either exemestane (25 mg/d) or further tamoxifen (20–30 mg/d) to achieve a total duration of endocrine therapy of 5 years. The allocation of treatment was double blind. Inclusion criteria permitted entry of patients with either ER-positive or ER-unknown tumors. Just over half of the women in both arms had node-negative disease, and one-third had received adjuvant chemotherapy. The primary endpoint was disease-free survival (DFS; time from randomization to recurrence of breast cancer at any site, diagnosis of a second primary breast cancer, or death from any cause). Secondary endpoints included overall survival (OS) and tolerability.

Outcome data from IES were first published in 2004 on the recommendation of the independent data monitoring and safety committee following the second planned interim analysis, which was triggered by the occurrence of half the total number of planned events. In this analysis, the unadjusted hazard ratio (HR) in the exemestane group as compared with the tamoxifen group was 0.68 (95% confidence interval [CI]: 0.56–0.82; P < 0.001), representing an absolute benefit in DFS of 4.7% (95% CI: 2.6–6.8) at 3 years after randomization (Table 1). There was no difference in OS although the number of events was low. Because this
treatment effect exceeded protocol-defined early stopping rules, early release of efficacy data was undertaken. By this point, more than 90% of patients had completed their planned treatment, thus diminishing the risk of confounding by nonprotocol-permitted crossover. At the time of this analysis, ER status was known for around 82% of cases, with just over 1% proving ER negative. The independent data monitoring and safety committee and the trial steering group agreed to perform a further analysis when 95% of patients had at least 3 years of follow-up. In addition, efforts were made to obtain ER status in as many of the ER-unknown patients as possible, and a supplementary analysis excluding those patients who enrolled with ER-unknown disease and were subsequently found to have ER-negative disease was prespecified.

This second analysis was published in 2007.22 Now with a median follow-up of 55.7 months, the unadjusted HR for DFS on an intention to treat basis was 0.76 (95% CI: 0.66–0.88; \( P = 0.0001 \)) in favor of exemestane (Table 1). This translated into a 3.3% absolute improvement in DFS at 2.5 years after randomization. At 5-year postrandomization, this benefit was maintained with an absolute improvement in DFS of 3.4%. Breast cancer-free survival, time to distant recurrence, and time to contralateral breast cancer were all significantly improved by switching to exemestane. The beneficial effect of exemestane on DFS appeared consistent across predefined subgroups according to age, nodal status, and previous chemotherapy. There had been 222 deaths in the exemestane group and 261 deaths in the tamoxifen group (HR = 0.85; 95% CI: 0.71–1.02; \( P = 0.08 \)). An additional analysis excluding 122 patients subsequently found to be ER negative demonstrated a 17% reduction in the relative risk of death (HR = 0.83; 95% CI: 0.69–1.00; \( P = 0.05 \)).

An updated analysis, with median follow-up of 91 months, was presented at the European CanCer Organisation–European Society for Medical Oncology congress in September 2009.23 In the intention-to-treat analysis,
a significant improvement in DFS and trend to improvement in OS were seen to be maintained several years after cessation of treatment (Table 1). When patients with ER-negative disease were excluded, a significant improvement in OS was now apparent. This corresponded to an absolute difference in OS of 1.4% at 5 years and 2.4% at 8 years.

In summary, IES has demonstrated a reduction in all types of DFS events for patients switched to exemestane after 2–3 years of tamoxifen vs patients remaining on tamoxifen. Furthermore, with longer follow-up and with the prespecified exclusion of patients recruited with unknown ER status and subsequently found to be ER negative, an improvement in OS has been established.

**TEAM trial**

The TEAM trial was initiated in 2001 as an open-label randomized comparison of exemestane (25 mg/daily) vs tamoxifen (20 mg/daily) as initial adjuvant therapy. However, following the publication of interim results of the IES trial in 2004, the protocol was modified such that all patients on the tamoxifen arm would switch to exemestane after 2.5–3 years. The modified study design included 2 co-primary endpoints: 1) DFS of tamoxifen vs exemestane at 2.75 years of median follow-up (the choice of 2.75 years represents the midpoint of the planned tamoxifen to exemestane crossover window; therefore, this analysis is essentially a test of upfront exemestane vs tamoxifen) and 2) DFS at 5 years of exemestane vs the tamoxifen–exemestane sequence. Events contributing to DFS were loco-regional or distant breast cancer recurrence, second primary or contralateral breast cancer, and death from any cause. Secondary endpoints included OS, relapse-free survival (RFS), and time to distant metastases. Only postmenopausal women with known ER and/or progesterone receptor (PR)-positive disease were eligible.

Almost 10,000 women were randomized to receive either upfront exemestane (n = 4,904) or the tamoxifen–exemestane sequence (n = 4,875). One hundred percent of cases were ER positive and/or PR positive, and 47% were node positive. Approximately one-third of patients in each arm had received adjuvant chemotherapy.

Results for the first co-primary endpoint were presented at the San Antonio Breast Cancer Symposium in 2008. For this analysis, all patients were censored at 2.75 years. Three hundred fifty-two DFS events had occurred in the exemestane arm vs 388 events in the tamoxifen arm, giving a HR of 0.89 (95% CI: 0.77–1.03; P = 0.12). Although the primary endpoint was not met, predefined secondary endpoints did achieve statistical significance with a HR of 0.85 (95% CI: 0.72–1.0; P = 0.05) for RFS and 0.81 (95% CI: 0.67–0.98; P = 0.03) for time to distant metastases in favor of exemestane. A potential confounder of these data is the significant proportion of patients who failed to complete 2.75 years of treatment. In particular, 1,434 (29.5%) patients randomized to the tamoxifen–exemestane sequence failed to complete 2.75 years of treatment, with 754 patients switching prematurely to exemestane.

The second co-primary endpoint (DFS at 5 years for upfront exemestane vs a tamoxifen–exemestane sequence) was presented at the San Antonio meeting in December 2009. The median follow-up was 5.1 years, with 60% having completed 5 years of follow-up. In this analysis, no benefit was demonstrated for upfront exemestane over the tamoxifen–exemestane sequence. Specifically, no improvement in DFS [HR 0.97 (95% CI: 0.88–1.08; P = 0.604)] or in OS

---

**Table 1 Analyses of International exemestane study**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Median follow-up</td>
<td>30.6 mo</td>
<td>55.7 mo</td>
<td>91 mo</td>
</tr>
<tr>
<td>DFS events</td>
<td>183 vs 266</td>
<td>354 vs 455</td>
<td>552 vs 641</td>
</tr>
<tr>
<td>DFS HR</td>
<td>0.68 (95% CI: 0.56–0.82; P &lt; 0.001)</td>
<td>0.76 (95% CI: 0.66–0.88; P = 0.0001)</td>
<td>0.84 (95% CI: 0.75–0.94; P = 0.002)</td>
</tr>
<tr>
<td>Absolute DFS benefit</td>
<td>4.7% (95% CI: 2.6–6.8) at 3 y postrandomization</td>
<td>3.4% (95% CI: 1.0–6.8) at 5 y postrandomization</td>
<td>2.8% (95% CI: 1.1–4.4) at 5 y postrandomization</td>
</tr>
<tr>
<td>Breast cancer-free survival</td>
<td>HR = 0.63 (95% CI: 0.51–0.77; P = 0.00001)</td>
<td>HR = 0.76 (95% CI: 0.65–0.89)</td>
<td>–</td>
</tr>
<tr>
<td>Time to distant recurrence</td>
<td>–</td>
<td>HR = 0.83 (95% CI: 0.71–0.99)</td>
<td>–</td>
</tr>
<tr>
<td>Time to contralateral breast cancer</td>
<td>HR = 0.44 (95% CI: 0.20–0.98) 0.04</td>
<td>HR = 0.57 (95% CI: 0.33–0.98)</td>
<td>–</td>
</tr>
<tr>
<td>OS (ITT)</td>
<td>HR = 0.88 (95% CI: 0.67–1.16; P = 0.37)</td>
<td>HR = 0.85 (95% CI: 0.71–1.02; P = 0.08)</td>
<td>HR = 0.89 (95% CI: 0.77–1.02; P = 0.09)</td>
</tr>
<tr>
<td>OS (ER, positive/unknown)</td>
<td>–</td>
<td>HR = 0.83 (95% CI: 0.69–1.00; P = 0.05)</td>
<td>HR = 0.86 (95% CI: 0.75–0.99; P = 0.04)</td>
</tr>
</tbody>
</table>

Abbreviations: DFS, disease-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival; ITT, intention-to-treat; ER, estrogen receptor; mo, months; y, years.
HR = 1.0 [95% CI: 0.89–1.14; P = 0.99]) was observed. Although the data are relatively immature, particularly for OS, the lack of any signal would suggest that a significant difference between the arms is unlikely to emerge. In this context, it is pertinent to consider the results of Breast International Group (BIG) 1–98, which similarly evaluated an upfront AI (letrozole) vs sequenced therapy incorporating tamoxifen. In this comparison, DFS was not significantly improved by sequenced therapy vs letrozole alone.26 A nonstatistically significant trend toward worse outcomes was observed in those patients randomized to tamoxifen followed by letrozole in comparison to letrozole monotherapy (HR = 1.05; 99% CI: 0.84–1.32) but not for the reverse sequence of letrozole followed by tamoxifen (HR = 0.96; 99% CI: 0.76–1.21). Reminiscent of the TEAM data, there were more early relapses in women randomized to tamoxifen followed by letrozole rather than letrozole alone.26

National Surgical Adjuvant Breast and Bowel Project B33 trial
In this randomized double-blind placebo-controlled trial, patients who were disease free after completing 5 years of adjuvant tamoxifen were randomly assigned to receive 5 years of exemestane (25 mg/d) or matched placebo.27 The primary endpoint was DFS (events defined as local or distant recurrence, second primary cancer, and death from any cause). Secondary endpoints were RFS, OS, and toxicity. Almost 1,600 of a planned 3,000 patients were recruited between May 2001 and October 2003. However, recruitment was terminated following the publication of data from the MA17 trial, which demonstrated a 42% reduction in the risk of recurrence for letrozole vs placebo in a similar patient population. Patients on study were unblinded, and those in the placebo group were offered exemestane. Forty-four percent of eligible patients receiving placebo opted to switch to exemestane although for the majority of these patients, this switch took place 6–12 months after unblinding. Despite the early closure of this trial and significant crossover from placebo to exemestane, the intention to treat primary analysis demonstrated a trend toward improved DFS (HR = 0.68; P = 0.07) together with a statistically significant improvement in RFS (HR = 0.44; P = 0.004) in those patients initially allocated exemestane.

ATENA Trial
The Adjuvant Post-Tamoxifen Exemestane (ATENA) trial was a randomized open-label study initiated by the Hellenic Society of Breast Surgeons to compare observation in 5 years of exemestane vs observation in postmenopausal woman who had completed 5–7 years of adjuvant tamoxifen.27 However, the ATENA trial was terminated having randomized 448 of a planned 1,800 patients following publication of the results of the MA17 trial.

MA27
The ongoing Canadian NCIC-MA27 trial randomized postmenopausal women with early breast cancer to receive adjuvant either anastrozole 1 mg/daily or exemestane 25 mg/daily for 5 years.28 The primary endpoint is event-free survival, and substudies to compare the effects of these drugs on bone mineral density (BMD) and breast density have been incorporated. Recruitment is now completed.

Toxicities of exemestane
The adverse effects of exemestane in this patient population have been characterized in large Phase III trials and their respective substudies and appear broadly similar to those of the nonsteroidal AIs. When interpreting toxicity data, particularly in respect to bone health and cardiovascular risk, it should be borne in mind that for both IES and TEAM, the data accrued are relative to tamoxifen and not to placebo. Exemestane is relatively well tolerated by the majority of patients; in the IES study, the rate of premature discontinuation of exemestane due to adverse events or patient refusal was 14%.22 However, it should be acknowledged that current evidence suggests a higher rate of noncompliance with hormonal therapy in the routine clinical setting.29,30 Patient education and proactive management of toxicity are thus essential components of care.

Vasomotor symptoms
Hot flashes are a common event in both tamoxifen- and exemestane-treated women. However, the frequency of this adverse event appears to be lower with exemestane. For example, a TEAM substudy, which addressed menopausal symptoms in 1,614 women, observed a peak in hot flashes at 3 months for both tamoxifen and exemestane, with a decline thereafter.31 At 12 months, hot flashes were significantly greater in the tamoxifen arm. An increased incidence in vasomotor symptoms has also been reported for the nonsteroidal AIs in comparison to tamoxifen.32,33 Furthermore, in patients intolerant of tamoxifen due to hot flashes, switching to exemestane or letrozole was associated with a reduction in severity of almost 50% at 6 weeks, albeit in a nonblinded study.34 On the other hand, the IES did not
identify a significant difference in vasomotor symptoms. This population, however, is not directly comparable, having already completed 2–3 years of hormonal therapy unlike the upfront comparison addressed in the TEAM substudy. Where vasomotor symptoms are troublesome both lifestyle advice and pharmacological interventions may be of benefit.

Musculoskeletal symptoms
Musculoskeletal symptoms, primarily classified as arthralgia, have been a consistent finding across trials of AIs. In the TEAM study, arthralgia was reported in 17.9% of patients after 2.75 years of upfront exemestane vs 9.2% in those randomized to tamoxifen (P < 0.001). In addition, an increased incidence of carpal tunnel syndrome was reported in both the IES and Arimidex, Tamoxifen, Alone or in Combination (ATAC) trials. Inflammatory indices, rheumatoid factor, and autoantibodies are typically normal, but characteristic tenosynovial changes have been demonstrated on magnetic resonance imaging. However, the underlying mechanism has yet to be elucidated. Management is typically with simple analgesics and nonsteroidal anti-inflammatory drugs. Nevertheless, in a proportion of patients, musculoskeletal symptoms may be debilitating and necessitate discontinuation of therapy.

Bone density
There is a clear association between levels of circulating estrogen and the risk of bone density loss and fracture in postmenopausal women. As the third-generation AIs reduce circulating estradiol to virtually undetectable levels, bone loss is a predictable mechanism-related toxicity. In contrast, the use of tamoxifen in postmenopausal women is associated with modest increases in bone density. Therefore, it has been important to address whether any anticancer benefits of exemestane might be diminished by a negative impact on bone health.

A significant increase in the incidence of fractures was observed in the exemestane arm of IES. With a median follow-up of 58 months, 162 (7%) patients in the exemestane group experienced a fracture compared with 115 (5%) patients in the tamoxifen group (odds ratio = 1.45 [1.13–1.87]; P = 0.003). A subprotocol of IES investigated bone metabolism in more detail in a subset of 206 patients in whom changes in bone density and biochemical markers of bone turnover were measured. No significant changes in bone density were seen in patients who remained on tamoxifen. However, switching to exemestane was associated with loss of bone density, which was most rapid in the first 6 months with ongoing loss recorded, albeit at a lower rate, in the periods of 6–12 month and 12–24 month. Specifically, in the first 6 months, BMD at the lumbar spine decreased from baseline by 2.7% (95% CI: 2.0–3.4; P < 0.0001), with a further decline of 1.0% (95% CI: 0.39–1.70; P = 0.002) occurring between 12 and 24 months. Consistent with these reductions in bone density, there was also a significant increase in biochemical markers of bone turnover. A similar pattern was observed in a smaller Italian study, which randomized 70 women who had completed 2–3 years of tamoxifen to either exemestane or continued tamoxifen. Here the switch to exemestane was associated with significant increases in markers of bone turnover and declines in BMD of 2.99% (P < 0.01) at the lumbar spine and 1.92% (P < 0.01) at the femoral neck at 24 months.

In TEAM, with median follow-up of 5.1 years, 5.1% of patients randomized to upfront exemestane had experienced fractures compared to 3.5% of those who switched from tamoxifen to exemestane (P < 0.001). Again, more detailed substudies provide support for a model where exemestane use leads to altered bone metabolism with resultant loss of bone density, ultimately predisposing to fracture. Specifically, a German substudy of the TEAM trial demonstrated significant increases in markers of bone turnover after 3, 6, and 12 months of treatment with exemestane, whereas treatment with tamoxifen resulted in significant reductions in these markers from baseline. Similarly, a US Oncology TEAM substudy observed significant loss of BMD with exemestane, and this effect was most marked in the first year.

The impact of exemestane on bone health in comparison to placebo rather than tamoxifen was addressed by a Norwegian study, which allocated women with low-risk breast cancer or ductal carcinoma in situ to receive 2 years of exemestane or placebo. In this study, no significant difference was detected in mean annual decline of BMD at the lumbar spine (2.17% vs 1.84%) although there was a significantly greater decline recorded at the femoral neck for exemestane (2.72% vs 1.48%; P = 0.024). However, the rate of bone loss in the placebo group was higher than expected, perhaps reflecting the high prevalence (88%) of vitamin D deficiency in this Scandinavian population.

It has been suggested that the androgenic structure of exemestane may promote bone synthesis and thus the overall effect of exemestane on bone may differ from that of the nonsteroidal AIs. Preclinical data, such as the demonstration of abrogated bone loss in ovariectomized rats treated with exemestane but not letrozole, exist to support this hypothesis. Furthermore, in a study of 84 healthy postmenopausal women randomized to receive either exemestane, letrozole, or
anastrozole for 24 weeks, there were no significant differences in markers of bone resorption, but treatment with exemestane was associated with a significant increase from baseline in serum procollagen type I N-terminal propeptide, a marker of bone formation.\textsuperscript{53} However, a separate study of similar design did not replicate this finding with all three AIs having similar effects on biochemical markers of both bone formation and bone resorption.\textsuperscript{56} Taken together with the observed increases in fracture risk attributable to exemestane in both the IES and TEAM trials, a clinically significant difference between exemestane and the nonsteroidal AIs would appear unlikely.\textsuperscript{57}

One attraction of the switch/sequential regimens employed by the IES and TEAM trials is that they appear to strike a pragmatic balance between offering improved prevention of cancer recurrence and protecting bone health. However, with appropriate monitoring of BMD, supplementation of calcium and vitamin D, and bisphosphonate therapy where appropriate, this toxicity can be mitigated.\textsuperscript{58,59} Nevertheless, for some women, bone health may be a consideration favoring a sequential or extended adjuvant strategy.

**Metabolic events**

The risk of cardiovascular disease increases rapidly in women following the menopause, and this is at least in part attributable to changes in serum lipids.\textsuperscript{60} As in other populations, increasing levels of low-density lipoprotein (LDL) cholesterol are associated with an increased risk of cardiovascular disease in postmenopausal women while higher levels of high-density lipoprotein (HDL) cholesterol exert a protective effect.\textsuperscript{61,62} The effect of exemestane on lipid profiles has been investigated relative to placebo, tamoxifen, and nonsteroidal AIs. Geisler and colleagues randomized 147 postmenopausal women with low-risk breast cancer to receive exemestane 25 mg/d or placebo for 2 years.\textsuperscript{53} Lipid profiles were determined 6 monthly whilst on treatment and at 6 months and 1 year posttreatment. Exemestane was associated with a small decrease in HDL cholesterol and apolipoprotein A1 levels, but this effect was reversible within 3–12 months of cessation of exemestane.

A Greek substudy of the TEAM trial assessed lipid profiles in 142 patients randomized to upfront tamoxifen or exemestane at baseline and then every 3 months for the first 12 months of treatment and at 18 and 24 months.\textsuperscript{63} There was a fall in total cholesterol levels in both arms, but LDL cholesterol levels fell significantly only in the tamoxifen arm. HDL cholesterol levels decreased across time in both groups, but levels were significantly higher in the tamoxifen arm. In the overall TEAM study, hyperlipidemia was reported less frequently in patients randomized to the tamoxifen-containing arm (2.8% vs 4.7%, \( P < 0.001 \)).\textsuperscript{25}

In the context of the switching strategy as addressed by IES, exemestane was not associated with a significant increase in hypercholesterolemia vs continued tamoxifen.\textsuperscript{22} However, a small Italian study, which randomized 60 overweight women who had completed 2–3 years of adjuvant tamoxifen to either continued tamoxifen or a switch to exemestane did report a significant increase in LDL cholesterol and fall in HDL cholesterol over the 1-year study period in patients receiving exemestane.\textsuperscript{64} The relative contribution of tamoxifen withdrawal rather than exemestane effect per se is not known but may be particularly relevant for the rise in LDL cholesterol, which was not observed in the comparison of exemestane with placebo described above.\textsuperscript{53} Interestingly, despite these potentially negative changes in lipid profiles, the switch to exemestane was actually associated with beneficial effects on body composition, with a significant decrease in fat mass. Similar changes in lipid profiles were observed in patients who had received 5 years of tamoxifen and were randomized to receive exemestane or observation within the ATENA trial;\textsuperscript{65} there was a significant decrease in HDL cholesterol in the exemestane arm whilst LDL cholesterol levels rose in both arms, likely indicating withdrawal of the beneficial tamoxifen effect.

A comparison of exemestane with letrozole and anastrozole in 90 healthy postmenopausal women reported an increase in atherogenic ratios of LDL cholesterol:HDL cholesterol for exemestane vs the nonsteroidal AIs.\textsuperscript{66}

Taken together, these data indicate that exemestane lacks the potentially cardioprotective lipid-altering effects of tamoxifen and, furthermore, may also be associated with modest reductions in levels of HDL cholesterol. However, the clinical significance of these changes is not clear. In particular, a clinically significant elevated risk of cardiovascular events has not been identified in adjuvant trials of exemestane. Similarly, the clinical significance, if any, of the differences reported for exemestane vs the nonsteroidal AIs on lipid profiles is not yet clear.

**Cardiovascular/thromboembolic events**

The EBCTCG meta-analysis has demonstrated a nonsignificant trend toward a lower incidence of cardiac deaths in women receiving tamoxifen,\textsuperscript{3} possibly reflecting beneficial effects on lipid profiles.\textsuperscript{66} Conversely, the use of tamoxifen was associated with a nonsignificant increase in the incidence of venous thromboembolic and cerebrovascular events.\textsuperscript{2}
No significant differences in cardiovascular events (deaths, myocardial infarctions, angina, cerebrovascular accidents), either on treatment or during follow-up, were reported by IES. However, the rate of venous thromboembolic events was significantly higher in patients randomized to continue tamoxifen (2.3% vs 1.2%, \( P = 0.004 \)). With median follow-up of 5.1 years, the TEAM study reported a higher incidence of hypertension in the exemestane arm (6% vs 4.5%, \( P = 0.001 \)). However, there were no differences in the incidence of myocardial ischemia or other serious cardiac events. Again, the risk of venous thromboembolism was significantly higher in the tamoxifen arm (0.9% vs 2.0%, \( P < 0.001 \)).

Although individual adjuvant trials of third-generation AIs have not demonstrated statistically significant differences in cardiovascular disease (excluding thromboembolic disease), numerical excesses have been evident in some trials. A meta-analysis of adjuvant AI trials has reported an increased rate of grade 3 to 5 cardiovascular events for the use of AIs in comparison to tamoxifen. However, the absolute risk was low with a number needed to treat for an event to occur of 160–180. It is important that cardiovascular risk factors are managed in the standard manner; it is not appropriate to administer tamoxifen in preference to an AI in order to achieve a putative cardioprotective effect.

Gynecologic toxicity

Gynecological toxicity is a well-established complication of tamoxifen, in particular, the development of endometrial hyperplasia, polyps, and cysts and a 3-fold increase in the risk of endometrial cancer from 0.6 per 1,000 women years to 1.9 per 1,000 women years. These toxicities reflect the agonist activity of tamoxifen within the uterus. Although the absolute risk of endometrial cancer remains low, many more women will experience invasive investigations and significant anxiety because of bleeding or discharge whilst on tamoxifen. In contrast, the AIs, with no estrogen agonist activity, have not been associated with an increased risk of endometrial cancer.

The IES trial reported significantly lower rates of vaginal bleeding (5.2% vs 7.6%, \( P = 0.002 \)), endometrial hyperplasia (0.2% vs 1.2%), and dilation and curettage (0.8% vs 1.8%, \( P = 0.006 \)) in women randomized to exemestane. The incidence of endometrial cancer was low and did not differ between arms. Transvaginal ultrasound was prospectively planned in a subset of 219 patients enrolled in an IES sub-study. As expected for patients who had received 2–3 years of tamoxifen, there was a high incidence of baseline abnormality with endometrial thickening observed in 62.6% of patients. The switch to exemestane was associated with a rapid decrease in endometrial thickening over the first 6 months with a slower decline thereafter.

Within the TEAM study, those patients randomized to tamoxifen experienced significantly higher rates of vaginal bleeding (3.1% vs 1.6%) and endometrial hyperplasia (2% vs 0%). In addition, there was a numerical, but not statistically significant, excess of endometrial cancer in the tamoxifen arm. A US Oncology substudy of 1,614 women treated within TEAM has provided a detailed assessment of menopausal symptoms occurring during the first year of treatment; exemestane use was associated with less vaginal discharge but with more vaginal dryness and a higher frequency of reduced libido.

**Predictive biomarkers for exemestane**

Initial hypothesis-generating data suggested that ER-positive/PR-negative cancers may exhibit greater sensitivity to aromatase inhibition than to tamoxifen. However, this has not been supported by subsequent data. For example, exemestane appeared to be equally effective in the PR-positive and PR-negative subsets in an unplanned analysis of the IES data set. Furthermore, in a prospectively planned analysis of the TEAM data set, PR was prognostic but did not predict preferential benefit for tamoxifen over exemestane. Similar prognostic but not predictive significance for PR expression has been identified in the BIG 1–98 and Trans-ATAC studies.

Bartlett and colleagues have presented data based on a subset of 4,308 patients in the TEAM trial for whom biomarker data could be obtained. Specifically, in a prospectively planned analysis, they investigated ER, PR, human epidermal growth factor receptor (HER) 1–3, and Ki67 as continuous variables relative to DFS for the first 2.75 years of the TEAM trial (ie, the upfront tamoxifen vs exemestane comparison). In this analysis, patients who were HER2/3 positive derived no additional benefit from exemestane over tamoxifen [HR 1.13 (95% CI: 0.82–1.55)]. In contrast, the additional benefit of exemestane appeared to be confined to
those with HER2/3-negative tumors (HR = 0.69 [95% CI: 0.53–0.88]). This is consistent with HER2/3 tumors having an intrinsic resistance to hormonal therapy. A similar pattern was identified in the Trans-ATAC dataset albeit with a low number of events occurring.\(^7\) How this may be modified by the widespread use of adjuvant HER2-directed therapies is not known.

Thus specific predictive markers to select patients who may preferentially benefit from early AI are lacking. However, in addition to considering putative predictive markers, current prognostic markers such as nodal status, grade, size, age, and PR levels might help to select those patients at higher risk of early recurrence, who will achieve a greater absolute benefit with upfront AI therapy. For example, Bartlett has presented data based on the Her2/3-negative subset in the TEAM study, showing a number needed to treat to prevent an early relapse of 160 for those patients defined as lower risk vs 20 for those in a higher risk category.\(^74\)

### Adjuvant exemestane in premenopausal women

As explained above, AI use is contraindicated in women with functioning ovaries. Nevertheless, given the benefits in DFS and/or OS reported for certain AI strategies in postmenopausal women, it has been important to ascertain whether similar benefits might accrue in premenopausal women who are rendered menopausal by ovarian ablation or suppression. This was addressed in the Austrian Breast and Colorectal Cancer Study Group-12 trial in which 1,803 premenopausal women were randomized to receive ovarian suppression with goserelin with either tamoxifen or anastrozole.\(^7\) With median follow-up of 47.8 months, there was no significant difference in DFS between the anastrozole and the tamoxifen groups (HR for disease progression in the anastrozole group, 1.10; 95% CI: 0.78–1.53; \(P = 0.59\)). Two ongoing trials will address this question further. The Suppression of Ovarian Function trial randomizes women to tamoxifen alone or to goserelin with either tamoxifen or exemestane. The Tamoxifen and Exemestane trial randomizes women to goserelin with either tamoxifen or exemestane. At present, the adjuvant use of ovarian suppression and an AI must be considered an investigational approach.

A separate issue is adjuvant AI use in premenopausal women who have experienced chemotherapy-induced amenorrhea. The majority of women who receive adjuvant chemotherapy will become amenorrheic during treatment with the incidence of permanent chemotherapy-induced amenorrhea increasing with age such that permanent cessation of menses is observed in most women over the age of 40.\(^76\) However, it is clear that chemotherapy-induced amenorrhea does not equate to permanent cessation of ovarian function and that aromatase inhibition may contribute to recovery of ovarian function via hypothalamic–pituitary feedback. For example, 12 of 45 women (median age 47, range 39–52) treated at the Royal Marsden who had been amenorrheic for 6 months postchemotherapy and who had biochemical evidence of ovarian suppression subsequently recovered ovarian function after commencing on AI.\(^77\) This included one patient who became pregnant without recovery of menstruation and another patient with biochemical recovery of ovarian function without menstruation. Thus, in this case, series AI use would appear to be potentially harmful in a quarter of such patients. For this reason, AIs should be used with great caution in this population as addressed by recent guidelines.\(^77,78\)

### Conclusion

The weight of evidence indicates that strategies that incorporate third-generation AIs are associated with improved DFS; however, the optimal strategy for incorporation of AIs into adjuvant therapy remains a matter of controversy. For those patients at the lowest risk of relapse, the absolute benefit may be minimal and tamoxifen monotherapy considered acceptable. On the other hand, for those patients at high risk of relapse, the use of an AI should be considered. The attempts to define subgroups that may gain most from an upfront AI have used complex modeling of biological and clinical risk features, which have resulted in defining patients who have a larger absolute benefit from the AI, rather than a relative increased benefit compared to tamoxifen, due to a higher clinical risk and with biological features suggesting generally less hormone-sensitive tumors. This is in contrast to the MA17 and IES trials which appear to show an increased benefit, and for some patients gains in OS, from an AI in populations that are enriched for hormone sensitivity by enrolling patients still disease free after 5 years or 2.75 years of tamoxifen, respectively.

Rather than considerations of efficacy, treatment choices in an individual patient may be influenced by the different toxicity profiles with more gynecological toxicity and venous thromboembolic disease occurring with tamoxifen vs arthralgia and the need for monitoring and treatment of bone health with aromatase inhibition. In this context, it may well be that a sequential strategy that should minimize toxicities would be the optimum choice.

As regards the comparative efficacy and toxicity of exemestane vs nonsteroidal AIs, these agents do have distinct...
pharmacokinetic and pharmacodynamic profiles, but the clinical significance of these differences will be best addressed by the ongoing comparative trials such as MA27 rather than by cross-trial comparisons. At present, exemestane should be used according to trial data as reflected in the product label.

Disclosure

The authors report no conflicts of interest in this work.

References


